Article Text

Download PDFPDF

Hepatotoxicity from pyrazinamide based anti-tuberculous therapy: protective effect from isoniazid and HIV infection?
Free
  1. A E Boyd
  1. Research Registrar, Homerton University Hospital NHS Trust, UK; aileen.boyd@homerton.nhs.uk

Statistics from Altmetric.com

In 1999 the American Thoracic Society (ATS), the Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of America (IDSA) endorsed a 2 month daily regimen of rifampin and pyrazinamide (2RZ) for the treatment of latent tuberculosis (TB) infection. This recommendation followed a prospective randomised trial in HIV infected persons showing that 2RZ had similar efficacy and safety to a 12 month regimen of daily …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.